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Abstract: As Nuclear Factor-κB (NF-κB) is a major transcription factor responding to cellular stress,
it is perhaps not surprising that is activated by hypoxia, or decreased oxygen availability. However,
how NF-κB becomes activated in hypoxia is still not completely understood. Several mechanisms
have been proposed and this review will focus on the main findings highlighting the molecules that
have been identified in the process of hypoxia induced NF-κB. In addition, we will discuss the role of
NF-κB in the control of the cellular response to hypoxia.
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1. Introduction
Hypoxia, or a decrease in oxygen availability, is both a physiological and pathological stimulus for
cells [1]. Different tissues are exposed to different oxygen tensions, and when the demand for oxygen
exceeds its supply, hypoxia ensues. This can be the case following tissue wounding, ischeamic stroke
or intense metabolic activity, such as the one encountered following pathogenic related infections
associated with increased macrophage infiltration. Hypoxia induces a comprehensive transcriptional
program that involves the activation of the transcription factor Hypoxia Inducible Factor family (HIF).
HIF is responsible for the induction of numerous genes involved in many different processes such as
angiogenesis, cell proliferation, cell death and autophagy [2,3]. Oxygen sensitivity is achieved by a
class of enzymes that are dioxygenases, called prolyl-hydroxylases (PHDs) and factor inhibiting HIF
(FIH). PHDs regulate HIF stability via the association of the ubiquitin ligase complex containing the
tumour suppressor von Hippel Lindau (VHL) [4], while FIH controls HIF association with the key
coactivators p300 and CREB Binding Protein (CBP), thus regulating HIF’s transcriptional activity [5].
However, the cellular response to hypoxia does not only rely on HIF, as many other transcription
factors have been shown to respond to hypoxia [2,6]. One of these is the family of transcription factors
Nuclear Factor-κB (NF-κB). In this review we will focus on the pathways described for the activation
of NF-κB in hypoxia and describe the roles of NF-κB in the cellular response to low oxygen. Of note, an
extensive crosstalk exists between HIF and NF-κB, which has been recently reviewed elsewhere [7–9].
2. Pathways for NF-κB Activation, Canonical, Non-Canonical and Atypical
NF-κB is a family of transcription factors that is composed by RelA, RelB, cRel, NF-κB1 (p105/p50)
and NF-κB2 (p100/p52) [10]. These transcription factors are usually held captive in the cytoplasm
by a family of inhibitors called Inhibitor of κB (IκBs) [10]. Upon stimulation by different stresses,
a number of pathways have been described that lead to nuclear accumulation and DNA-binding of
NF-κB [11]. These pathways, can be subdivided in canonical, non-canonical and atypical pathways.
The most well understood pathway is the canonical or classical pathway of NF-κB activation, involving
activation of Transforming Growth Factor-B activating kinase (TAK1) and the Inhibitor of κB kinase
complex (IKK), composed of IKKα, IKKβ and IKKγ or NF-κB essential modulator (Nemo) [12,13]. The
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non-canonical mode of NF-κB activation relies on NF-κB inducing kinase (NIK) and IKKγ homodimer
activation [12,13]. On the other hand, atypical pathways leading to NF-κB activation usually do not
require the IKK complex and act directly on the IκBs [13].
NF-κB activation pathways are heavily regulated by changes in ubiquitination of several
components [14]. In fact, the study of NF-κB activation pathways has propelled the discovery of
the function of different ubiquitin chains as well as novel deubiquinase enzymes, such Lysine 63 (K63)
ubiquitin and Cyld [15], linear ubiquitin and otulin [16]. Furthermore, a study, investigating how
Tumour Necrosis Factor (TNF) receptor engagement triggers the NF-κB activation pathways, identified
a multitude of different ubiquitin chains present at the receptor, including K11 and K48 [17].
3. Activation of NF-κB by Hypoxia, Role of PHDs and FIH
For the activation of most pathways leading to NF-κB, a ligand is usually required to bind to a
receptor, such as a cytokine or recognition of foreign DNA or RNA [18]. However, a stimulus such
as DNA damage activates NF-κB by sensor kinases in the nucleus culminating in the activation of
cytoplasmic IKK [19]. As such, how hypoxia induces NF-κB is far from clear. As mentioned above, for
the activation of HIF, the cell relies on oxygen sensors such as PHDs and FIH [20]. Intuitively, these
enzymes could provide the mechanism by which other signaling pathways in the cell are activated by
reduced oxygen availability. A seminal study by the group of Cormac Taylor, suggested that indeed
PHDs could link oxygen sensing to NF-κB activation, by directly impacting on IKKs themselves [6].
Here, PHD1 was identified as the isoform with the higher level of control over IKK activity (Figure 1).
Since then, several other studies identified a role for PHDs in the control of NF-κB, however whether
this requires the hydroxylase activity of the enzyme has received conflicting reports.
While it is clear that in certain cell types and/or tissues, PHD activity inhibition can lead to NF-κB
activation [6,21], other studies suggested that PHDs might just act as a bridge between IKKγ and the
ubiquitination machinery [22]. Furthermore, while it is not firmly established if PHDs hydroxylate
any of the IKKs in the cell, hydroxylation sites have been found in ubiquitin ligases Uve1a and Ubc13,
two enzymes required for NF-κB activation following Interleukin 1β (IL-1β) stimulation [23]. However,
additional studies are required to identify the functional role of these modifications, in terms of their
effects in the activation of NF-κB in hypoxia. Interestingly, our group had identified these enzymes as
being required for hypoxia induced NF-κB [24,25].
More recently, PHD2 has been shown to act as a RelA co-activator, however, it is not clear if its
enzymatic activity is required for such actions [26]. As such, additional studies designed to uncover
hydroxylation sites and their functional roles are necessary to consolidate the theory that activation of
the NF-κB pathway in hypoxia is mediated by PHDs.
Perhaps the best connection between hydroxylase activity and NF-κB is focused on FIH. Proteomic
studies leading to the identification of new FIH targets, identified a number of components of the
NF-κB pathways as being hydroxylated, including IκBs and NF-κB1 and NF-κB2 [27]. More recently,
a study revealed potential targets in the upstream pathway, in particular in de-ubiquitinase enzyme
OTUB1 [23,28]. Despite all of these targets, the functional significance of FIH-dependent hydroxylation
on these proteins’ function remains unclear, as mutations of the acceptor asparagines have revealed very
little information, as to whether they are important or not [27,29]. The exception to this, is hydroxylation
of OTUB1 by FIH, where mutation of the acceptor asparagine changes the interactome of OTUB1 and
gives rises to metabolic changes in the cell [28]. However, the importance of OTUB1 for the activation
of NF-κB in hypoxia has not been demonstrated. As such, additional work is required to fully delineate
the role of these dioxygenases in the control or activation of the pathways leading to NF-κB activity.
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Figure 1. Mechanism of hypoxia induced Nuclear Factor-κB (NF-κB). Schematic diagram depicting 
the overview of the mechanism behind hypoxia induced NF-κB. Hypoxia induced NF-κB has been 
shown to require Calcium, Transforming Growth Factor-B activating kinase (TAK1) and Inhibitor of 
κB kinase complex (IKK). In addition, contributions from dioxygenases such as prolyl-hydroxylases 
(PHDs) and factor inhibiting HIF (FIH) have been reported. Unanswered questions into the 
mechanisms of hypoxia induced NF-κB are highlighted as questions marks. SENPs-Sentrin/SUMO 
specific proteases; S2-Sumo-2. 
4. Activation of NF-κB by Hypoxia, Role of TAK and IKK 
As mentioned above, to ensure a rapid NF-κB response, NF-κB subunits are not synthetized de 
novo, but kept inactive in the cytoplasm and, when necessary, activated by different signaling 
pathways. With the exception of the IKK-independent atypical pathways [30], the IKK kinase 
complex is a key element in the NF-κB signaling cascade. In this complex, IKKα and IKKβ are the 
two catalytic kinase subunits. Both of them are physiologically essential as knockout mice are, 
respectively, neonatal or embryonic lethal [31]. 
When, in 1994, it was reported for the first time that hypoxia can activate NF-κB, an IKK-
independent mechanism of induction was hypothesized (see below) [32]. Although a number of 
studies followed that pivotal finding, additional mechanistic insights into NF-κB activation following 
hypoxia were lacking for another decade. We, and others, uncovered a potential mechanism 
regulating hypoxia-induced first wave of NF-κB activation, where IKK has a crucial role [24,33] 
(Figure 1). Our work showed that hypoxia leads to the NF-κB activation very rapidly, varying from 
5 to 30 minutes. The important role of IKK was unveiled by multiple investigating approaches. Both 
Figure 1. Mechanism of hypoxia induced Nuclear Factor-κB (NF-κB). Schematic diagram depicting the
overview of the mechanism behind hypoxia induced NF-κB. Hypoxia induced NF-κB has been shown
to require Calcium, Transforming Growth Factor-B activating kinase (TAK1) and Inhibitor of κB kinase
complex (IKK). In addition, contributions from dioxygenases such as prolyl-hydroxylases (PHDs)
and factor inhibiting HIF (FIH) have been reported. Unanswered questions into the mechanisms
of hypoxia induced NF-κB are highlighted as questions marks. SENPs-Sentrin/SUMO specific
proteases; S2-Sumo-2.
4. Activation of NF-κB by Hypoxia, Role of TAK and IKK
As mentioned above, to ensure a rapid NF-κB response, NF-κB subunits are not synthetized
de novo, but kept inactive in the cytoplasm and, when necessary, activated by different signaling
pathways. With the exception of the IKK-independent atypical pathways [30], the IKK kinase complex
is a key element in the NF-κB signaling cascade. In this complex, IKKα and IKKβ are the two catalytic
kinase subunits. Both of them are physiologically essential as knockout mice are, respectively, neonatal
or embryonic lethal [31].
When, in 1994, it was reported for the first time that hypoxia can activate NF-κB,
an IKK-independent mechanism of induction was hypothesized (see below) [32]. Although a number
of studies followed that piv tal finding, additional mechanistic insights into NF-κB ac vation following
hypoxia were lacking for anothe decade. We, and others, uncovered a potential mechanism regulating
hypoxia-induced first wave of NF-κB activation, where IKK h s a crucial role [24,33] (Figure 1). Our
work showed that ypoxia leads to the NF-κB activation very rapidly, varying from 5 to 30 min.
The important role of IKK was unveiled by multiple investigating approaches. Both in cancer
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cells and primary cells, the inhibition or deletion of IKK caused, respectively, partial or complete
reduction of hypoxia-induced phosphorylation of IκBα on Serine 32 and 36. Furthermore, also the
NF-κB DNA binding was affected [24,25]. These results were also conserved in the model organism
Drosophila melanogaster, where hypoxia activates NF-κB in a IKK-dependent manner [34]. In this study,
Ird5 (the fly IKK homologue) was found to be crucial to allow the transcription of NF-κB target genes
activated by hypoxia.
In addition, we found that Transforming Growth Factor Activating Kinase 1 (TAK1), a member of
the mitogen-activated protein kinase (MAPK) family, was required for IKK activation in this context
(Figure 1). This role of TAK1 was already known after treatment with different stimuli, such as TNF-α,
IL-1β and lipopolysaccharide (LPS) [35]. A number of evidences confirmed the critical importance of
TAK1 also for the hypoxia-induced NF-κB activation via IKK, ultimately reflecting in the induction of
specific NF-κB-dependent target gene expression. Among the known upstream factors involved in
TAK1 activation, we found that Ca2+ release and consequent calcium/calmodulin-dependent kinase 2
(CaMK2) activity are required to obtain a functional activation of the NF-κB pathway in response
to hypoxia (Figure 1). In addition, we showed that the E2 ubiquitin-conjugating enzyme Ubc13 is
necessary, indicating that K63 ubiquitin chains are important for hypoxia induced NF-κB. In fact,
Ubc13 expression was found to be increased in hypoxia, and specific Ubc13 depletion prevented IKK
and IκBα phosphorylation [24]. We also identified XIAP as one of the possible E3-ligase interacting
with Ubc13, essential for the induction of hypoxia-activated NF-κB pathway [25]. Both Ubc13 and
XIAP are known to be required for K63-linked ubiquitin chains [36] (Figure 1).
Although in Drosophila melanogaster, the roles of Ca2+ and TAK1 have not been investigated, Cyld
was identified as a negative regulator of hypoxia-induced NF-κB activation. In mammalian cells, Cyld
is a NF-κB target, as well as a negative regulator of IKK activity [37], however its role in the hypoxia
response has not been completely elucidated yet. However, our findings are in accordance with a
previous study conducted by An and colleagues [38]. Specifically, they described Cyld as mediator
of NF-κB activation after prolonged hypoxia, in cells expressing the E6 viral protein. These studies
further highlight the role of K63-ubiquitin chains in hypoxia induced NF-κB.
Thus, TAK1-IKK axis seems to be the major mechanism underlying the activation of the NF-κB
pathway following hypoxia stimuli, also taking into consideration its evolutionary conservation.
However, the existence of other cell/tissue specific regulatory mechanisms activated in particular
conditions, such as prolonged hypoxia, is still possible and further studies are needed.
5. Activation of NF-κB by Hypoxia, Modulation of IκB
In the cytoplasmic signaling cascade activated by hypoxia to induce NF-κB, IκBα has primary
importance. This is one of the five cellular proteins recognized as NF-κB inhibitors. IκB family
members, through their ankyrin repeats, are able to bind and mask the nuclear localization signal of
NF-κB subunits, keeping them inactive into the cytoplasm [39].
As previously mentioned (see above), in the first study showing the NF-κB activation by
hypoxia [32], a prominent role of a tyrosine phosphorylation of IκBα, involved in the dissociation of this
inhibitory protein, as well as in the NF-κB DNA binding, was reported. In contrast to canonical NF-κB
activation, characterized by IκBα degradation, hypoxia-induced NF-κB activation is not characterized
by IκBα degradation. As such, an IKK-independent mechanism of activation was suggested. However,
we, and others, demonstrated the crucial role played by IKK in the regulation of hypoxia-induced
NF-κB [24,33,34]. Phosphorylation of IκBα on Ser32/36 is an important characteristic of the activation
of the pathway via TAK1-IKK, on the other hand, no role for Tyrosine 42 (Y42) of IκBα could be
identified, when mutants where analysed [24].
Nevertheless, IκBα is not degraded after hypoxia induction, as hypoxia prevents its ubiquitination.
Particularly, the lack of IκBα degradation depends on its conjugation with Sumo-2/3 of Lysine 21 [24].
While Sumo-1 conjugation of IκBα has been linked to NF-κB inhibition [40], Sumo-2/3 conjugation,
induced by hypoxia, seems to contribute to NF-κB activation (Figure 1). Specifically, our data suggested
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that hypoxia might prevent the activation of Sumo proteases, thus preventing desumoylation of
IκBα [24,25]. Thus far, different models regulating IκBα sumoylation have been discovered in various
contexts [41,42]. Interestingly, phosphorylated and sumoylated IκBα has been shown to be nuclear and
regulate transcription mediated by polycomb [43]. Doubtless, further studies focused on sumoylated
IκBα and sumo protease activity during the hypoxia response will be informative to complement the
current knowledge.
6. Role of NF-κB in the Cellular Response to Hypoxia
Despite the mechanisms leading to NF-κB activation in hypoxia being still under investigation,
it is now clear that indeed NF-κB responds to this stimulus. As such, the functional consequences of
this activation also need to be investigated. For the majority of studies investigating cancer cells, NF-κB
activation following hypoxia results in decreased apoptosis and increased angiogenesis [24,44–46].
However, the situation is different in tissues such as the brain and the heart, where NF-κB activation
seems to have a more complicated role both inducing and repressing apoptosis depending on
context [47].
The functional consequences of hypoxia induced NF-κB has been mainly studied in disease
models. One major response controlled by NF-κB under this stimulus is cell death. Under hypoxia,
NF-κB has been shown to modulate the expression of numerous proteins involved in the control of
apoptosis such as Bcl-2 family members as well as inhibitors of apoptosis [24,48,49]. As such hypoxia
induced NF-κB is important for the survival programme in cancer.
In addition, hypoxia induced NF-κB has been shown to upregulate the expression of IL-8 [24],
an important chemokine for the induction of angiogenesis [50], thus contributing to the overall
neo-vasculature generation occurring in hypoxia.
Hypoxia induced NF-κB has also been shown to induce the expression of protein involved
in motility and adhesion such as matrix metalloproteases (MMPs) and SDF-1 [51–53]. These have
been seen in cancer cell lines but also in immune and neuronal cells in conditions such arthritis and
stroke [51–53].
In conclusion, hypoxia induced NF-κB is important for many of the cellular responses elicited
by this stimulus, in particular for prevention of apoptosis, induction of angiogenesis and promoting
motility of cells.
7. Conclusions
At least in some cell types, hypoxia is a relatively mild (yet robust) activator of the NF-κB response
in comparison to, for example, cytokine stimulation, and this may have implications for which set
of target genes are activated by NF-κB in hypoxia. Hypoxia induced NF-κB is IKK dependent and
relies on the canonical signaling cascade for this activation (Figure 1). However, the involvement
of dioxygenase such as PHDs and FIH has been reported and these might have important roles in
the control of the NF-κB pathway under different cellular contexts and following prolonged hypoxia
exposures (Figure 1). It is therefore likely that hypoxia induced NF-κB is multifaceted and may well
involve several or all of the mechanisms mentioned above. Additional studies are required to answer
the remaining questions concerning the mechanisms of NF-κB activation in hypoxia (Figure 1).
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